Press Releases

BOSTON and SYDNEY — 24 November 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America, announces today that the board of directors has received the resignation of GI Dynamics non-executive directors Anne...

BOSTON and SYDNEY – 17 November 2017 – GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will provide a corporate update and discuss 2017 third quarter...

BOSTON and SYDNEY — 13 November 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America has received notification from its notified body SGS United Kingdom, Limited (SGS) that SGS will withdraw the CE...

LISBON, PORTUGAL — 25 September 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces that new data has been released from the Institute for Clinical...

BOSTON and SYDNEY— 23 August 2017— GI Dynamics® Inc. (ASX:GID), a medical device company that commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity announces the appointment of medical and financial markets veteran Juliet Thompson to...

BOSTON and SYDNEY — 14 August 2017 — GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, welcomed new members to the GI Dynamics Scientific Advisory Board (SAB),...

BOSTON and SYDNEY – 10 August 2017 – GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will update investors on 2017 second quarter results as reported...

BOSTON and SYDNEY – 26 July 2017 – GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, today announced the selection of Proven Process Medical Devices, Inc. (PPMD) as...

BOSTON and SYDNEY —  20 June 2017 — GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity announced additional members of the GI Dynamics Scientific Advisory Board (SAB),...

BOSTON and SYDNEY, 16 June 2017— GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity today announced a US $5,000,000 convertible note financing. GI Dynamics conducted...